BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitari de Bellvitge (8)
2022
-
A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression
Blood Advances, Vol. 6, Núm. 21, pp. 5763-5773
-
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
Cancers, Vol. 14, Núm. 7
2021
-
Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative
Annals of Hematology, Vol. 100, Núm. 3, pp. 825-830
2020
-
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
Experimental Hematology and Oncology
2015
-
CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival
Journal of Pathology, Vol. 235, Núm. 3, pp. 445-455
2011
-
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
Blood, Vol. 117, Núm. 6, pp. 1799-1805
-
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Nature, Vol. 475, Núm. 7354, pp. 101-105
2008
-
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication
Clinical Cancer Research, Vol. 14, Núm. 1, pp. 155-161